Bionorica SE, corporate

Bionorica SE,

19.07.2017 - 13:31:13

New Research Director at Bionorica

Dr Dirk Bredenbröker joins leading herbal medicine manufacturerNeumarkt, 19 July 2017 - Dr Dirk Bredenbröker was appointed head of R&D at Bionorica at the beginning of July. He will oversee a team of more than 40 people and report directly to Professor Michael A. Popp, owner and CEO of Bionorica SE. "We are delighted to have gained the services of Dr Bredenbröker, an expert who brings 18 years of experience in the pharmaceutical industry, particularly in cross-border clinical research and various therapeutic areas," says Professor Popp. The goal was to work together to bring R&D at Bionorica to the next level. "Bionorica is the market leader in scientifically substantiated phytomedicine, a segment which is expanding worldwide. Our research activities, in which we invested around 14 percent of our revenue in 2016, have played a crucial role in this success." This R&D investment quota puts Bionorica among the forerunners in the German pharmaceutical industry1. The company has also established research alliances with more than 500 leading institutes, hospitals and universities worldwide. Dr Bredenbröker, who has headed the international R&D divisions at four pharmaceutical companies, is already looking forward to his new professional challenge: "Bionorica is an innovative company in the field of phytotherapy, and in particular, in respect of research into new active ingredients and herbal medicines. We use the latest methods to prove their effectiveness and safety. In keeping with Bionorica's 'phytoneering' philosophy, my team and I will be focusing on developing the connection between cutting-edge clinical research and the wealth of experience afforded by herbal medicine." The 47-year-old consultant in clinical pharmacology completed his doctorate in pulmonary medicine at the Philipps University of Marburg in 1997. In his last position Dr Bredenbröker served for four years as Vice President of the Established Products and Global Medical Affairs Division at Takeda Pharmaceuticals International AG in Zurich. Previously, at the Japanese pharmaceutical company's European Development Center, his responsibilities had included clinical development in immunology and respiratory tracts. A native of Wolfsburg, Dr Bredenbröker resides in Constance and Neumarkt, has a 17-year-old daughter, and likes to spend time with his partner at Lake Constance. Dr Bredenbröker's predecessor, Dr Aldo Ammendola, has left Bionorica.Sources: 1) According to the German Association for the Pharmaceutical Industry (BPI), the R&D quota of the pharmaceutical industry in Germany was just above 12 percent in 2015. The 2016 data are due to be published in April 2018. Corporate profile Patients want effective and tolerable medications and so herbal medicines are the preferred option. Bionorica, located in Neumarkt in the Oberpfalz region, is one of the world's leading manufacturers of scientifically researched herbal medicines. Doctors, pharmacists and patients in more than 50 countries trust in our effective products with few side effects. In 2016, Bionorica SE achieved a net turnover of EUR 253.1 million. The company's equity ratio is around 77 per cent. Every day, over 1,500 employees at 17 Bionorica locations worldwide work on the continuation of this success story, which began in Nuremberg more than 80 years ago. Based on the 'phytoneering' strategy, Bionorica decodes the extensive active ingredient potential of plants (phytos) using state-of-the-art research and technology (engineering). The result: highly effective medicines with few side effects. Our research and development priorities are for the treatment of symptoms in the respiratory tract, urinary tract, immune system and also women's health. Our range also includes products for the liver, rheumatism and sleep disorders.

Contact for press and media Bionorica SE Dirk Alexander Lude Head of Global Corporate Communications Kerschensteinerstrasse 11-15 92318 Neumarkt, Germany Tel. +49/(0)9181/231-7289 Fax +49/(0)9181/231-67289 Email: dirk.lude@bionorica.dehttp://bionorica.de/fuer-journalisten.html

End of Media ReleaseAdditional features:Picture: http://newsfeed2.eqs.com/bionorica/593931.htmlSubtitle: Dr. Dirk Bredenbröker ist neuer Forschungsleiter bei Bionorica (c) Dr. Dirk BredenbrökerDocument: http://n.eqs.com/c/fncls.ssp?u=KUJNRDXBXJDocument title: New Research Director at Bionorica Issuer: Bionorica SE Key word(s): Research/Technology

19.07.2017 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

593931  19.07.2017 

@ dgap.de